Vaccine against malaria

Final trial data for the 1. malaria vaccine candidate called RTS,S/AS01 to reach phase 3 of clinical trials show that it is partially effective up to four years after being applicated. The results suggest the vaccine could prevent a significant number of new cases, particularly in areas with high rates of transmission. It is now up for the European Medicines Agency to evaluate the data from the trial.

Original source


Register for receiving PharmaAround news, register for PharmAround events.
Continue registration

Recently visited